SALZBURG, Austria--(BUSINESS WIRE)--MSACL 2015 –– Thermo Fisher Scientific, the world leader in serving science, today announced that it received the in vitro diagnostics device (IVDD) CE mark for its Thermo Scientific Prelude MD HPLC, Endura MD mass spectrometer and ClinQuan MD software.
Available for general in vitro diagnostic use in Europe, clinical laboratories now have access to a high-performance liquid chromatograph, mass spectrometer and LC-MS software designed and manufactured for in vitro diagnostic use in analyzing patient samples as components of laboratory-developed tests. The products will be exhibited at the 2nd Annual European Conference on Clinical Mass Spectrometry, MSACL EU 2015 Conference, Booth 12-13, and at the Salzburg Congress Centre, Salzburg, Austria.
"We're strongly committed to bringing the advantages of LC-MS to the clinical market," said Bradley Hart, strategic director, life sciences mass spectrometry, clinical markets, for Thermo Fisher. “These three products are part of a larger initiative to make mass spectrometry more useful and accessible to clinicians.”
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit http://www.thermofisher.com.